// App-Quantinova.ai

1251 : Significant growth suppressive effects of TOPK and MELK inhibitors in kidney cancer

Researchers

Presenter

  • Taigo Kato

Principal Investigators

  • Hiroyuki Inoue

  • Seiya Imoto

  • Yoshinori Tamada

  • Takashi Miyamoto

  • Yo Matsuo

  • Yusuke Nakamura

  • Jae-Hyun Park

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Tokyo, Tokyo, Japan

  • OncoTherapy Science, Inc., Kanagawa, Japan

Locations

  • United States

  • Japan

Companies

  • OncoTherapy Science,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hand foot syndrome

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • Forkhead box M1

  • Maternal Embryonic Leucine Zipper Kinase

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Rapacan

  • L-Tyrosine

  • OTS167

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved